Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Operating Margin (2016 - 2025)

Vanda Pharmaceuticals' Operating Margin history spans 16 years, with the latest figure at 70.53% for Q4 2025.

  • On a quarterly basis, Operating Margin fell 5120.0% to 70.53% in Q4 2025 year-over-year; TTM through Dec 2025 was 69.95%, a 4950.0% decrease, with the full-year FY2025 number at 69.95%, down 4950.0% from a year prior.
  • Operating Margin hit 70.53% in Q4 2025 for Vanda Pharmaceuticals, down from 55.61% in the prior quarter.
  • Over the last five years, Operating Margin for VNDA hit a ceiling of 18.22% in Q2 2021 and a floor of 81.99% in Q1 2025.
  • Historically, Operating Margin has averaged 16.28% across 5 years, with a median of 14.09% in 2023.
  • Biggest five-year swings in Operating Margin: skyrocketed 1672bps in 2021 and later tumbled -6253bps in 2025.
  • Tracing VNDA's Operating Margin over 5 years: stood at 12.7% in 2021, then decreased by -19bps to 10.28% in 2022, then plummeted by -252bps to 15.67% in 2023, then fell by -23bps to 19.33% in 2024, then tumbled by -265bps to 70.53% in 2025.
  • Business Quant data shows Operating Margin for VNDA at 70.53% in Q4 2025, 55.61% in Q3 2025, and 73.21% in Q2 2025.